Cognition Therapeutics Alzheimer’s drug CT1812 is in a new round of clinical testing to see how it affects other medications being taken by Alzheimer’s patients in the US.
Cognition Therapeutics Alzheimer’s drug CT1812 is in a new round of clinical testing to see how it affects other medications being taken by Alzheimer’s patients in the US.